Tag Archives: Chad Messer

Akebia surges on anemia drug deal; is a much bigger breakout looming?

The News: Akebia Therapeutics Inc. (Cambridge MA) leaped 18% Tuesday (May 16, 2017) sparked by news the fledgling dialysis treatment developer and Swiss backer Vifor Pharma Group Ltd. (Glattburg) agreed… Read more »

Week’s opening stock salvo: Esperion, Nektar, CytomX soar; Aevi Genomic thrashed

Esperion Therapeutics Inc. (Nasdaq: ESPR) stock recently recovered big time from last Amgen-induced beat down to touch an 18-month high after the company outlined its path to FDA approval for its… Read more »

Health sector’s biggest winners & losers as of March 17, 2017

Seres Therapeutics Inc. (Nasdaq: MCRB) led advancing issues, soaring $2.71, or 29% for the week, to $12.04. The small microbiome-therapeutics platform company released its fourth-quarter results earlier Thursday (March 16,… Read more »

Vericel Stem-Cell Therapy Reduces Deaths and Hospitalizations in Advanced Heart Failure Patients

VERICEL CORP.’s (Ann Arbor MI) stem-cell therapy helped reduce deaths and hospitalizations in advanced heart failure patients, according to data from a mid-stage study, potentially providing a treatment that could… Read more »